Table 7 Probabilistic sensitivity analysis results according to PFS and OS. Amounts are presented in MXN pesos
TKI | Mean total cost | Incremental Cost | Effectiveness | Incremental Effectiveness | ICER |
|---|---|---|---|---|---|
Progression Free Survival (PFS) | |||||
Gefitinib | $161,781.47 | – | 8.180 | – | – |
Erlotinib | $218,411.28 | $56,629.81 | 6.701 | −1.48 | Dominated |
Afatinib | $347,853.28 | $129,442.00 | 9.457 | 1.28 | $101,363.54 |
Overall Survival (OS) | |||||
Gefitinib | $157,891.46 | – | 27.098 | – | – |
Erlotinib | $207,416.43 | $49,524.98 | 21.774 | −5.32 | Dominated |
Afatinib | $347,423.61 | $140,007.18 | 37.095 | 10.00 | $14,004.90 |